ABBISKO-B (02256) has risen more than 9% again. As of the time of writing, the stock was up 8.76%, trading at HK$12.91 with a turnover of HK$21.9969 million. The company announced that the results of the global multicenter Phase III MANEUVER study for its self-developed novel, oral, highly selective, and potent small molecule CSF-1R inhibitor, Beijiemai (Pimitinib Hydrochloride Capsules, ABSK021), were officially published in the international medical journal The Lancet on March 5. This publication marks a significant milestone for ABBISKO-B, reflecting the quality of clinical research, data integrity, and international academic recognition of this innovative therapy.